Back to Search Start Over

Cystathionine β -Synthase Regulates the Proliferation, Migration, and Invasion of Thyroid Carcinoma Cells.

Authors :
Jiang QY
Li JM
Jing MR
Zhang YX
Zhang QQ
Cai CB
Wang D
Qi HW
Li T
Li YZ
Ji XY
Wu DD
Source :
Oxidative medicine and cellular longevity [Oxid Med Cell Longev] 2022 Jun 27; Vol. 2022, pp. 8678363. Date of Electronic Publication: 2022 Jun 27 (Print Publication: 2022).
Publication Year :
2022

Abstract

Thyroid cancer is considered to be one of the most common endocrine tumors worldwide. Cystathionine β -synthase (CBS) plays a crucial role in the occurrence of several types of malignancies. And yet, the mechanism of action of CBS in the growth of thyroid carcinoma cells is still unrevealed. We found that CBS level in thyroid carcinoma tissue was higher than that in adjacent normal tissue. The overexpression of CBS enhanced the proliferation, migration, and invasion of thyroid cancer cells, while the downregulation of CBS exerted reverse effects. CBS overexpression reduced the levels of cleaved caspase-3 and cleaved poly ADP-ribose polymerase in thyroid cancer cells, whereas CBS knockdown showed reverse trends. CBS overexpression decreased reactive oxygen species (ROS) levels but increased the levels of Wnt3a and phosphorylations of phosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB/AKT), mammalian target of rapamycin (mTOR), β -catenin, and glycogen synthase kinase-3 beta, while CBS knockdown exerted opposite effects. In addition, CBS overexpression promoted the growth of xenografted thyroid carcinoma, whereas CBS knockdown decreased the tumor growth by modulating angiogenesis, cell cycle, and apoptosis. Furthermore, aminooxyacetic acid (an inhibitor of CBS) dose-dependently inhibited thyroid carcinoma cell growth. CBS can regulate the proliferation, migration, and invasion of human thyroid cancer cells via ROS-mediated PI3K/AKT/mTOR and Wnt/ β -catenin pathways. CBS can be a potential biomarker for diagnosing or prognosing thyroid carcinoma. Novel donors that inhibit the expression of CBS can be developed in the treatment of thyroid carcinoma.<br />Competing Interests: The authors declare that they have no competing interests.<br /> (Copyright © 2022 Qi-Ying Jiang et al.)

Details

Language :
English
ISSN :
1942-0994
Volume :
2022
Database :
MEDLINE
Journal :
Oxidative medicine and cellular longevity
Publication Type :
Academic Journal
Accession number :
35795862
Full Text :
https://doi.org/10.1155/2022/8678363